Pharmacokinetic studies in children with cancer

Critical Reviews in Oncology/Hematology

Volumn 52, Issue 3, 2004, Pages 173-197

  Groninger, E ^a   Proost, J H ^b   De Graaf, S S N ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti neoplastic drugs; Child; Haematology; Individualized dosing; Oncology; Pharmacodynamics; Pharmacokinetically guided; Pharmacokinetics

Indexed keywords

ALKALOID DERIVATIVE; ALKYLATING AGENT; ALLOPURINOL; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; CARBAMAZEPINE; CARBOPLATIN; CHLORMETHINE; CHLORPROMAZINE; CISPLATIN; CYCLOPHOSPHAMIDE DERIVATIVE; CYTARABINE; CYTOCHROME P450 3A; DACARBAZINE; DEXAMETHASONE; ETOPOSIDE; FLUCONAZOLE; IFOSFAMIDE; ISOPHOSPHORAMIDE MUSTARD; MERCAPTOPURINE; METHOTREXATE; PHENYTOIN; PLATINUM DERIVATIVE; PREDNISONE; PROCARBAZINE; TENIPOSIDE; TIOGUANINE; UNINDEXED DRUG;

AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CORRELATION ANALYSIS; CYTOTOXICITY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CLEARANCE; LEUKEMIA; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA; NEUROBLASTOMA; OSTEOSARCOMA; REVIEW; SIDE EFFECT; SOLID TUMOR; VOMITING;

ANTINEOPLASTIC AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METABOLIC CLEARANCE RATE; NEOPLASMS; THERAPEUTIC EQUIVALENCY;

EID: 9944233453     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2004.08.007     Document Type: Review

References (249)

1. M.V. Relling, H.L. McLeod, L.C. Bowman, and V.M. Santana Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin Clin Pharmacol Ther 56 5 1994 503 511
2. A. Davidson, R. Gowing, and S. Lowis Phase II study of 21-day schedule oral etoposide in children New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG) Eur J Cancer 33 11 1997 1816 1822
3. D.S. Sonnichsen, R.C. Ribeiro, X. Luo, P. Mathew, and M.V. Relling Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors Clin Pharmacol Ther 58 1 1995 99 107
4. J.H. Rodman, M. Abromowitch, J.A. Sinkule, F.A. Hayes, G.K. Rivera, and W.E. Evans Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial J Clin Oncol 5 7 1987 1007 1014
5. W.E. Evans, J.H. Rodman, and M.V. Relling Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia J Pharmacol Exp Ther 260 1 1992 71 77
6. J.A. Sinkule, C.F. Stewart, W.R. Crom, E.T. Melton, G.V. Dahl, and W.E. Evans Teniposide (VM26) disposition in children with leukemia Cancer Res 44 3 1984 1235 1237
7. C.E. Gidding, J.M. Fock, and J.H. Begeer Proceedings of the 34th Annual Meeting of the American Society of Clinical Oncology ASCO, Los Angeles, CA, May 16-19 Vincristine disposition and neurotoxicity in children 1998 2203
8. W.E. Evans, C.B. Pratt, R.H. Taylor, L.F. Barker, and W.R. Crom Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients Cancer Chemother Pharmacol 3 3 1979 161 166
9. T.S. Goh, K.Y. Wong, B. Lampkin, J. O'Leary, and D. Gnarra Evaluation of 24-hour infusion of high-dose methotrexate - pharmacokinetics and toxicity Cancer Chemother Pharmacol 3 3 1979 177 180
10. C. Rask, F. Albertioni, S.M. Bentzen, H. Schroeder, and C. Peterson Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukaemia - a logistic regression analysis Acta Oncol 37 3 1998 277 284
11. W.E. Evans, W.R. Crom, and C.F. Stewart Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia Lancet 1 8373 1984 359 362
12. J.D. Borsi, and P.J. Moe Systemic clearance of methotrexate in the prognosis of acute lymphoblastic leukemia in children Cancer 60 12 1987 3020 3024
13. 2 in children with acute lymphoblastic leukemia Cancer 60 1 1987 5 13
14. W.E. Evans, W.R. Crom, and M. Abromowitch Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukaemia. Identification of a relation between concentration and effect N Engl J Med 314 8 1986 471 477
15. N. Graf, K. Winkler, M. Betlemovic, N. Fuchs, and U. Bode Methotrexate pharmacokinetics and prognosis in osteosarcoma J Clin Oncol 12 7 1994 1443 1451
16. G. Saeter, T.A. Alvegard, I. Elomaa, A.E. Stenwig, T. Holmstrom, and O.P. Solheim Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study J Clin Oncol 9 10 1991 1766 1775
17. N. Delepine, G. Delepine, H. Cornille, F. Brion, P. Arnaud, and J.-C. Desbois Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma Anticancer Res 15 1995 489 494
18. N.M. Marina, J. Rodman, and S.J. Shema Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors J Clin Oncol 11 3 1993 554 560
19. D.R. Newell, A.D. Pearson, and K. Balmanno Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group J Clin Oncol 11 12 1993 2314 2323
20. W.R. Crom, A.M. Glynn Barnhart, and J.H. Rodman Pharmacokinetics of anticancer drugs in children Clin Pharmacokinet 12 3 1987 168 213
21. M. Rowland, and T.N. Tozer Age and weight D. Balado F. Klass L. Stead R.D. Magee Clinical pharmacokinetics: concepts and applications 1995 William and Wilkins Philadelphia 230 247
22. D.S. Alberts, H.S. Chen, and R. Liu Bleomycin pharmacokinetics in man. I. Intravenous administration Cancer Chemother Pharmacol 1 3 1978 177 181
23. S.M. Yule, A.V. Boddy, and M. Cole Cyclophosphamide pharmacokinetics in children Br J Clin Pharmacol 41 1 1996 13 19
24. M.J. Tasso, A.V. Boddy, L. Price, R.A. Wyllie, A.D. Pearson, and J.R. Idle Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients Cancer Chemother Pharmacol 30 3 1992 207 211
25. V.I. Avramis, R. Biener, and M. Krailo Biochemical pharmacology of high dose 1-β-d-arabinofuranosylcytosine in childhood acute leukemia Cancer Res 47 24 Pt 1 1987 6786 6792
26. A.P. Periclou, and V.I. Avramis NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias Cancer Chemother Pharmacol 39 1-2 1996 42 50
27. H.L. McLeod, M.V. Relling, and W.R. Crom Disposition of antineoplastic agents in the very young child Br J Cancer Suppl 18 1992 S23 29
28. C.T. Tan, C. Hancock, and P. Steinherz Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer Cancer Res 47 11 1987 2990 2995
29. C.H. Pui, S.S. de Graaf, and L.W. Dow Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia Cancer Res 48 18 1988 5348 5352
30. W.R. Crom, C.A. Riley, A.A. Green, F.A. Hayes, C. Pratt, and W. Evans Doxorubicin disposition in children and adolescents with cancer Drug Intell Clin Pharm 17 1983 448
31. A.V. Boddy, S.M. Yule, R. Wyllie, L. Price, A.D. Pearson, and J.R. Idle Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children Cancer Res 53 16 1993 3758 3764
32. M.G. Donelli, M. Zucchetti, and A. Robatto Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia Med Pediatr Oncol 24 3 1995 154 159
33. S.S. de Graaf, H. Bloemhof, D.E. Vendrig, and D.R. Uges Vincristine disposition in children with acute lymphoblastic leukemia Med Pediatr Oncol 24 4 1995 235 240
34. D.S. Sonnichsen, C.A. Hurwitz, C.B. Pratt, J.J. Shuster, and M.V. Relling Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors J Clin Oncol 12 3 1994 532 538
35. D.S. Sonnichsen, and M.V. Relling Clinical pharmacokinetics of paclitaxel Clin Pharmacokinet 27 4 1994 256 269
36. F.M. Balis, J.S. Holcenberg, and D.G. Poplack General principles of chemotherapy P.A. Pizzo D.G. Poplack Principles and practice of pediatric oncology 1997 Lippincott-Raven Philadelphia 215 272
37. R. Skinner, A.D.J. Pearson, L. Price, M.G. Coulthard, and A.W. Craft The influence of age on nephrotoxicity following chemotherapy in children Br J Cancer 66 Suppl. XVIII 1992 S30 35
38. F.D. Juma, H.J. Rogers, and J.R. Trounce Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites Eur J Clin Pharmacol 19 6 1981 443 451
39. S.M. Yule, N.K. Foreman, C. Mitchell, N. Gouldon, P. May, and H.P. McDowell High-dose cyclophosphamide for poor-prognosis and recurrent pediatric brain tumors: a dose-escalation study J Clin Oncol 15 10 1997 3258 3265
40. S.M. Yule, A.V. Boddy, and M. Cole Cyclophosphamide metabolism in children Cancer Res 55 4 1995 803 809
41. C.M.J. Bagley, F.W. Bostick, and V.T.J. DeVita Clinical pharmacology of cyclophosphamide Cancer Res 33 2 1973 226 233
42. H.T. Mouridsen, and E. Jacobsen Pharmacokinetics of cyclophosphamide in renal failure Acta Pharmacol Toxicol Copenh 36 5 1975 409 414
43. V. Bramwell, R.T. Calvert, G. Edwards, H. Scarffe, and D. Crowther The disposition of cyclophosphamide in a group of myeloma patients Cancer Chemother Pharmacol 3 4 1979 253 259
44. R.J. Motzer, S.C. Gulati, and W.P. Tong Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors Cancer Res 53 16 1993 3730 3735
45. U. Schuler, G. Ehninger, and T. Wagner Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites Cancer Chemother Pharmacol 20 3 1987 248 252
46. U. Schuler, P. Waidelich, H. Kolb, T. Wagner, and G. Ehninger Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients Eur J Clin Pharmacol 40 5 1991 521 523
47. S.M. Yule, D. Walker, and M. Cole The effect of fluconazole on cyclophosphamide metabolism in children Drug Metab Dispos 27 3 1999 417 421
48. L.J. Ayash, J.E. Wright, and O. Tretyakov Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response J Clin Oncol 10 6 1992 995 1000
49. A.V. Boddy, S.M. Yule, R. Wyllie, L. Price, A.D. Pearson, and J.R. Idle Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration Cancer Chemother Pharmacol 38 2 1996 147 154
50. A.V. Boddy, S.M. Yule, R. Wyllie, L. Price, A.D. Pearson, and J.R. Idle Comparison of continuous infusion and bolus administration of ifosfamide in children Eur J Cancer 31A 5 1995 785 790
51. A.V. Boddy, M. Cole, A.D. Pearson, and J.R. Idle The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion Cancer Chemother Pharmacol 36 1 1995 53 60
52. M.P. Ducharme, M.L. Bernstein, C.P. Granvil, B. Gehrcke, and I.W. Wainer Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers Cancer Chemother Pharmacol 40 6 1997 531 533
53. A.V. Boddy, M. Proctor, D. Simmonds, M.J. Lind, and J.R. Idle Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients Eur J Cancer 31A 1 1995 69 76
54. M.J. Lind, J.M. Margison, T. Cerny, N. Thatcher, and P.M. Wilkinson Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma Cancer Res 49 3 1989 753 757
55. A.V. Boddy, M. English, A.D. Pearson, J.R. Idle, and R. Skinner Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics [see comments] Eur J Cancer 32A 7 1996 1179 1184
56. F. Doz, and R. Pinkerton What is the place of carboplatin in paediatric oncology? Eur J Cancer 30A 2 1994 194 201
57. 2 in children Med Pediatr Oncol 18 6 1990 459 465
58. F. Doz, S. Urien, and E. Chatelut A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children Cancer Chemother Pharmacol 42 3 1998 250 254
59. E. Chatelut, A.V. Boddy, and B. Peng Population pharmacokinetics of carboplatin in children Clin Pharmacol Ther 59 4 1996 436 443
60. N.M. Marina, J.H. Rodman, and D.J. Murry Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors J Natl Cancer Inst 86 7 1994 544 548
61. T. Madden, M. Sunderland, V.M. Santana, and J.H. Rodman The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer Clin Pharmacol Ther 51 6 1992 701 707
62. R. Riccardi, A. Riccardi, and A. Lasorella Clinical pharmacokinetics of carboplatin in children Cancer Chemother Pharmacol 33 6 1994 477 483
63. B. Peng, A.V. Boddy, and M. Cole Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients Eur J Cancer 31A 11 1995 1804 1810
64. D.J. Murry, J.T. Sandlund, L.M. Stricklin, and J.H. Rodman Pharmacokinetics and acute renal effects of continuously infused carboplatin Clin Pharmacol Ther 54 4 1993 374 380
65. S. Oguri, T. Sakakibara, and H. Mase Clinical pharmacokinetics of carboplatin J Clin Pharmacol 28 3 1988 208 215
66. S.J. Harland, D.R. Newell, Z.H. Siddik, R. Chadwick, A.H. Calvert, and K.R. Harrap Pharmacokinetics of cis-diammine-11-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function Cancer Res 44 4 1984 1693 1697
67. -2 divided over three consecutive days Br J Cancer 61 3 1990 460 464
68. D.R. Newell, Z.H. Siddik, and L.A. Gumbrell Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin Eur J Cancer Clin Oncol 23 9 1987 1399 1405
69. M.E. Tonda, R.L. Heideman, W.P. Petros, H.S. Friedman, D.J. Murry, and J.H. Rodman Carboplatin pharmacokinetics in young children with brain tumors Cancer Chemother Pharmacol 38 5 1996 395 400
70. G. Koren, S. Weitzman, J. Klein, and G. Moselhy Comparison of carboplatin pharmacokinetics between an anephric child and two children with normal renal function Med Pediatr Oncol 21 5 1993 368 372
71. A.H. Calvert A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel Semin Oncol 24 1 Suppl 2 1997 S2
72. M.W. English, R. Skinner, A.D. Pearson, L. Price, R. Wyllie, and A.W. Craft Dose-related nephrotoxicity of carboplatin in children Br J Cancer 81 2 1999 336 341
73. M.W. English, S.P. Lowis, and B. Peng Pharmacokinetically guided dosing of carboplatin and etoposide during peritoneal dialysis and haemodialysis Br J Cancer 73 6 1996 776 780
74. M.J. Egorin, D.A. Van Echo, and S.J. Tipping Pharmacokinetics and dosage reduction of cis-diammine(11-cyclobutanedicarboxylato)platinum in patients with impaired renal function Cancer Res 44 11 1984 5432 5438
75. S.J. Harland, L.A. Gumbrell, and A. Horwich Carboplatin dose in combination chemotherapy for testicular cancer [see comments] Eur J Cancer 27 6 1991 691 695
76. A. Horwich, D.P. Dearnaley, and J. Nicholls Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors J Clin Oncol 9 1 1991 62 69
77. D.I. Jodrell, M.J. Egorin, and R.M. Canetta Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer [see comments] J Clin Oncol 10 4 1992 520 528
78. D.J. Murry, J.T. Sandlund, L.M. Stricklin, and J.H. Rodman Pharmacokinetics and acute renal effects of continuously infused carboplatin Clin Pharmacol Ther 54 4 1993 374 380
79. H. Thomas, A.V. Boddy, and M.W. English Prospective validation of renal function-based carboplatin dosing in children with cancer: a United Kingdom Children's Cancer Study Group Trial J Clin Oncol 18 21 2000 3614 3621
80. B. Peng, A.V. Boddy, and M. Cole Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients Eur J Cancer 31A 11 1995 1804 1810
81. C. Dominici, F. Petrucci, S. Caroli, A. Alimonti, A. Clerico, and M.A. Castello A pharmacokinetic study of high-dose continuous infusion cisplatin in children with solid tumors J Clin Oncol 7 1 1989 100 107
82. T. Murakami, S. Inoue, K. Sasaki, and T. Fujimoto Studies on age-dependent plasma platinum pharmacokinetics and ototoxicity of cisplatin Sel Cancer Ther 6 3 1990 145 151
83. W.R. Crom, W.E. Evans, and C.B. Pratt Cisplatin disposition in children and adolescents with cancer Cancer Chemother Pharmacol 6 1 1981 95 99
84. B. Peng, M.W. English, and A.V. Boddy Cisplatin pharmacokinetics in children with cancer Eur J Cancer 33 11 1997 1823 1828
85. P.A. Reece, I. Stafford, J. Russell, M. Khan, and P.G. Gill Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity J Clin Oncol 5 2 1987 304 309
86. P.T. Daley-Yates, and D.C. McBrien Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin Biochem Pharmacol 33 19 1984 3063 3070
87. M. Bues Charbit, J.C. Gentet, J.L. Bernard, V. Breant, J.P. Cano, and C. Raybaud Continuous infusion of high-dose cisplatin in children: pharmacokinetics of free and total platinum Eur J Cancer Clin Oncol 23 11 1987 1649 1652
88. J.H. Schellens, J. Ma, A.S. Planting, and M.E. van der Burg Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours Br J Cancer 73 12 1996 1569 1575
89. P.T. Daley-Yates, and D.C. McBrien Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin Biochem Pharmacol 33 19 1984 3063 3070
90. 2) in childhood malignancies: clinical tolerability and pharmacokinetics Pediatr Hematol Oncol 4 1 1987 33 42
91. 2) methotrexate therapy Pediatr Hematol Oncol 3 2 1986 127 134
92. W.E. Evans, C.F. Stewart, and P.R. Hutson Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemia Drug Intell Clin Pharm 16 11 1982 839 842
93. I.G. Kerr, J. Jolivet, J.M. Collins, J.C. Drake, and B.A. Chabner Test dose for predicting high-dose methotrexate infusions Clin Pharmacol Ther 33 1 1983 44 51
94. Y.M. Wang, W.W. Sutow, M.M. Romsdahl, and C. Perez Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma Cancer Treat Rep 63 3 1979 405 410
95. C.R. Pinkerton, S.G. Welshman, J.G. Kelly, R.G. Shanks, and J.M. Bridges Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia Cancer Chemother Pharmacol 10 1 1982 36 39
96. F.M. Balis, J.L. Savitch, and W.A. Bleyer Pharmacokinetics of oral methotrexate in children Cancer Res 43 5 1983 2342 2345
97. P. Sonneveld, F.W. Schultz, K. Nooter, and K. Hahlen Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate Cancer Chemother Pharmacol 18 2 1986 111 116
98. W.E. Evans, W.R. Crom, J.A. Sinkule, G.C. Yee, C.F. Stewart, and P.R. Hutson Pharmacokinetics of anticancer drugs in children Drug Metab Rev 14 5 1983 847 886
99. G. Koren, G. Ferrazzini, H. Sohl, I. Robieux, D. Johnson, and E. Giesbrecht Chronopharmacology of methotrexate pharmacokinetics in childhood leukemia Chronobiol Int 9 6 1992 434 438
100. G. Ferrazzini, H. Sohl, I. Robieux, D. Johnson, E. Giesbrecht, and G. Koren Diurnal variation of methotrexate disposition in children with acute leukaemia Eur J Clin Pharmacol 41 5 1991 425 427
101. F.M. Balis, S.L. Jeffries, and B. Lange Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? Am J Pediatr Hematol Oncol 11 3 1989 324 326
102. R. Erttmann, S. Bielack, and G. Landbeck Kinetics of 7-hydroxy- methotrexate after high-dose methotrexate therapy Cancer Chemother Pharmacol 15 2 1985 101 104
103. J.D. Borsi, E. Sagen, I. Romslo, L. Slordal, and P.J. Moe 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia Cancer Chemother Pharmacol 27 2 1990 164 167
104. R.G. Buice, W.E. Evans, and J. Karas Evaluation of enzyme immunoassay, radioassay, and radioimmunoassay of serum methotrexate, as compared with liquid chromatography Clin Chem 26 13 1980 1902 1904
105. 2 to children with acute lymphoblastic leukemia Med Pediatr Oncol 18 3 1990 217 224
106. W.E. Evans, A. Tsiatis, W.R. Crom, G.M. Brodeur, T.C. Coburn, and C.B. Pratt Pharmacokinetics of sustained serum methotrexate concentrations secondary to gastrointestinal obstruction J Pharm Sci 70 11 1981 1194 1198
107. I.D. Goldman, V. Gupta, J.C. White, and S. Loftfield Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid "rescue" protocols Cancer Res 36 1 1976 276 279
108. J.H. Rodman, M. Sunderland, and R.L. Kavanagh Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients Cancer Res 50 14 1990 4267 4271
109. J. Ochs, J. Rodman, and M. Abromowitch A phase II study of combined methotrexate and teniposide infusions prior to reinduction therapy in relapsed childhood acute lymphoblastic leukemia: a Pediatric Oncology Group Study J Clin Oncol 9 1 1991 139 144
110. W.E. Evans, and M.L. Christensen Drug interactions with methotrexate J Rheumatol 12 Suppl 12 1985 15 20
111. D.G. Liegler, E.S. Henderson, M.A. Hahn, and V.T. Oliverio The effect of organic acids on renal clearance of methotrexate in man Clin Pharmacol Ther 10 6 1969 849 857
112. J.W. Paxton Interaction of probenecid with the protein binding of methotrexate Pharmacology 28 2 1984 86 89
113. D.A. Gewirtz, and S.A. Holt Protein binding as a component of drug interaction in cellular pharmacokinetic studies. Effects of probenecid on transport and accumulation of methotrexate in Ehrlich ascites tumor cells in vitro Biochem Pharmacol 34 6 1985 747 754
114. P. Coassolo, M. Valentin, M. Bourdeaux, and C. Briand Modification of human serum albumin binding of methotrexate by folinic acid and certain drugs used in cancer chemotherapy Eur J Clin Pharmacol 17 2 1980 123 127
115. G. Ferrazzini, J. Klein, H. Sulh, D. Chung, E. Griesbrecht, and G. Koren Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia J Pediatr 117 5 1990 823 826
116. K. Yamamoto, Y. Sawada, Y. Matsushita, K. Moriwaki, F. Bessho, and T. Iga Delayed elimination of methotrexate associated with piperacillin administration Ann Pharmacother 31 1997 1261 1262
117. N. Delepine, G. Delepine, H. Cornille, F. Brion, P. Arnaud, and J.C. Desbois Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma Anticancer Res 15 2 1995 489 494
118. F.M. Balis, J.S. Holcenberg, and D.G. Poplack Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study Blood 92 10 1998 3569 3577
119. W.E. Evans, M.V. Relling, J.H. Rodman, W.R. Crom, J.M. Boyett, and C.H. Pui Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia N Engl J Med 338 8 1998 499 505
120. F. Odoul, C. Le Guellec, and J.-P. Lamagnere Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach Fund Clin Pharmacol 13 5 1999 595 604
121. P. Lafolie, S. Hayder, O. Bjork, L. Ahstrom, J. Liliemark, and C. Peterson Large interindividual variations in the pharmacokinetics of oral 6-mercaptopurine in maintenance therapy of children with acute leukaemia and non-Hodgkin lymphoma Acta Paediatr Scand 75 5 1986 797 803
122. P. Lafolie, S. Hayder, O. Bjork, and C. Peterson Intraindividual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia Eur J Clin Pharmacol 40 6 1991 599 601
123. Y. Kato, T. Matsushita, K. Chiba, N. Hijiya, T. Yokoyama, and T. Ishizaki Dose-dependent kinetics of orally administered 6-mercaptopurine in children with leukemia J Pediatr 119 2 1991 311 316
124. S. Zimm, J.M. Collins, and R. Riccardi Variable bioavailability of oral mercaptopurine N Engl J Med 308 17 1983 1005 1009
125. C.A. Arndt, F.M. Balis, and C.L. McCully Bioavailability of low-dose vs. high-dose 6-mercaptopurine Clin Pharmacol Ther 43 5 1988 588 591
126. G. Koren, A.M. Langevin, N. Olivieri, E. Giesbrecht, A. Zipursky, and M. Greenberg Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia Am J Dis Child 144 10 1990 1135 1137
127. J. Welch, L. Lennard, G.C. Morton, and J.S. Lilleyman Pharmacokinetics of mercaptopurine: plasma drug and red cell metabolite concentrations after an oral dose Ther Drug Monit 19 4 1997 382 385
128. H. Sulh, G. Koren, C. Whalen, S. Soldin, A. Zipursky, and M. Greenberg Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia Clin Pharmacol Ther 40 6 1986 604 609
129. L. Lennard, D. Keen, and J.S. Lilleyman Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations Clin Pharmacol Ther 40 3 1986 287 292
130. P. Zuccaro, S. Guandalini, and R. Pacifici Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia Ther Drug Monit 13 1 1991 37 41
131. S. Zimm, J.M. Collins, D. O'Neill, B.A. Chabner, and D.G. Poplack Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol Clin Pharmacol Ther 34 6 1983 810 817
132. Y. Kato, T. Matsushita, H. Uchida, S. Egi, T. Yokoyama, and K. Mohri Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism Eur J Clin Pharmacol 42 6 1992 619 622
133. R. Riccardi, F.M. Balis, P. Ferrara, A. Lasorella, D.G. Poplack, and R. Mastrangelo Influence of food intake on bioavailability of oral 6-mercaptopurine in children with acute lymphoblastic leukemia Pediatr Hematol Oncol 3 4 1986 319 324
134. G.E. Rivard, C. Infante Rivard, M.F. Dresse, J.M. Leclerc, and J. Champagne Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival Chronobiol Int 10 3 1993 201 204
135. G.E. Rivard, C. Infante Rivard, C. Hoyoux, and J. Champagne Maintenance chemotherapy for childhood acute lymphoblastic leukaemia: better in the evening Lancet 2 8467 1985 1264 1266
136. F.M. Balis, S.L. Jeffries, and B. Lange Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? Am J Pediatr Hematol Oncol 11 3 1989 324 326
137. S. Zimm, L.J. Ettinger, and J.S. Holcenberg Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion Cancer Res 45 4 1985 1869 1873
138. L. Endresen, S.O. Lie, I. Storm Mathisen, H.E. Rugstad, and O. Stokke Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug Ther Drug Monit 12 3 1990 227 234
139. L. Lennard, and J.S. Lilleyman Are children with lymphoblastic leukaemia given enough 6-mercaptopurine? Lancet 2 8562 1987 785 787
140. L. Lennard, J.S. Lilleyman, J. Van Loon, and R.M. Weinshilboum Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia Lancet 336 8709 1990 225 229
141. W.E. Evans, M. Horner, Y.Q. Chu, D. Kalwinsky, and W.M. Roberts Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia J Pediatr 119 6 1991 985 989
142. F. Innocenti, R. Danesi, and A. Di Paolo Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate Cancer Chemother Pharmacol 37 5 1996 409 414
143. F.M. Balis, J.S. Holcenberg, and S. Zimm The effect of methotrexate on the bioavailability of oral 6-mercaptopurine Clin Pharmacol Ther 41 4 1987 384 387
144. L. Lennard, and J.S. Lilleyman Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukaemia [published erratum appears in J Clin Oncol 1990;8(3):567] J Clin Oncol 7 12 1989 1816 1823
145. G. Koren, G. Ferrazini, and H. Sulh Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children [see comments] N Engl J Med 323 1 1990 17 21
146. P.C. Adamson, F.M. Balis, S.M. Steinberg, D.G. Poplack, and J.S. Holcenberg Pharmacokinetics of mercaptopurine in children with acute lymphocytic leukemia [letter; comment] N Engl J Med 323 22 1990 1565 1566
147. Y.Y. Hon, and W.E. Evans Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach Clin Chem 44 2 1998 388 400
148. N. Erb, D.O. Harms, and G. Janka Schaub Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine Cancer Chemother Pharmacol 42 4 1998 266 272
149. L. Lennard, H.A. Davies, and J.S. Lilleyman Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer 68 1 1993 186 190
150. L.W. Brox, L. Birkett, and A. Belch Clinical pharmacology of oral thioguanine in acute myelogenous leukemia Cancer Chemother Pharmacol 6 1 1981 35 38
151. B.J. Kitchen, F.M. Balis, D.G. Poplack, M. O'Brien, C.E. Craig, and P.C. Adamson A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion Clin Cancer Res 3 5 1997 713 717
152. C.T. Tan, N. Wollner, and T. Trippett Pharmacologic-guided trial of sequential methotrexate and thioguanine in children with advanced malignancies J Clin Oncol 12 9 1994 1955 1962
153. K. Lu, J.A. Benvenuto, G.P. Bodey, J.A. Gottlieb, M.G. Rosenblum, and T.L. Loo Pharmacokinetics and metabolism of β-2′-deoxythioguanosine and 6-thioguanine in man Cancer Chemother Pharmacol 8 1 1982 119 123
154. P.H. Konits, M.J. Egorin, and D.A. Van Echo Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma Cancer Chemother Pharmacol 8 2 1982 199 203
155. K. Schmiegelow, H. Schroder, and M. Schmiegelow Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: dose adjustments by white cell counts or by pharmacokinetic parameters? Cancer Chemother Pharmacol 34 3 1994 209 215
156. V.I. Avramis, K.I. Weinberg, and J.K. Sato Pharmacology studies of 1-β-d-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug Cancer Res 49 1 1989 241 247
157. W. Plunkett, J.O. Liliemark, and T.M. Adams Saturation of 1-β-d-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-β-d-arabinofuranosylcytosine therapy Cancer Res 47 11 1987 3005 3011
158. H.C. van Prooijen, A.W. Dekker, and K. Punt The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse Br J Haematol 57 2 1984 291 299
159. M.F. Ozkaynak, V.I. Avramis, S. Carcich, and J.A. Ortega Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia Med Pediatr Oncol 31 6 1998 475 482
160. V.I. Avramis, S. Wiersma, and M.D. Krailo Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group [see comments] Clin Cancer Res 4 1 1998 45 52
161. J. Ochs, J.A. Sinkule, M.K. Danks, A.T. Look, W.P. Bowman, and G. Rivera Continuous infusion high-dose cytosine arabinoside in refractory childhood leukemia J Clin Oncol 2 10 1984 1092 1097
162. M.V. Relling, R.K. Mulhern, D. Fairclough, D. Baker, and C.H. Pui
163. H.D. Preisler, Y.M. Rustum, N. Azarnia, and R. Priore Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside Cancer Chemother Pharmacol 19 1 1987 69 74
164. W. Plunkett, S. Iacoboni, E. Estey, L. Danhauser, J.O. Liliemark, and M.J. Keating Pharmacologically directed ara-C therapy for refractory leukemia Semin Oncol 12 2 Suppl 3 1985 20 30
165. J. Boos, E. Real, W. Schulze, J. Wolff, T. Euting, and H. Jurgens Investigation of the variability of etoposide pharmacokinetics in children Int J Clin Pharmacol Ther Toxicol 30 11 1992 495 497
166. M.K. Arnaout, K.M. Radomski, and D.K. Srivastava Treatment of childhood acute myelogenous leukemia with an intensive regimen (AML-87) that individualizes etoposide and cytarabine dosages: short- and long-term effects Leukemia 14 2000 1736 1742
167. R. Erttmann, M. Grandt, N. Erb, M. Garbrecht, and G. Landbeck The pharmacokinetics of doxorubicin Klin Padiatr 198 3 1986 271 276
168. J.M. Reid, T.W. Pendergrass, M.D. Krailo, G.D. Hammond, and M.M. Ames Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Children's Cancer Study Group report Cancer Res 50 20 1990 6525 6528
169. G. Rivera, W.E. Evans, G.V. Dahl, G.C. Yee, and C.B. Pratt Phase I clinical and pharmacokinetic study of 4′-(9-acridinylamino)-methanesulfon- m-anisidide in children with cancer Cancer Res 40 11 1980 4250 4253
170. W.P. Petros, J.H. Rodman, J. Mirro Jr., and W.E. Evans Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia Cancer Chemother Pharmacol 27 5 1991 397 400
171. P.A. Speth, F.A. van de Loo, P.C. Linssen, H.M. Wessels, and C. Haanen Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin Clin Pharmacol Ther 40 6 1986 643 649
172. J. Robert, and L. Gianni Pharmacokinetics and metabolism of anthracyclines Cancer Surv 17 1993 219 252
173. S.C. Piscitelli, K.A. Rodvold, D.A. Rushing, and D.A. Tewksbury Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer Clin Pharmacol Ther 53 5 1993 555 561
174. J. Cummings, and J.F. Smyth Pharmacology of adriamycin: the message to the clinician Eur J Cancer Clin Oncol 24 4 1988 579 582
175. C.Y. Paul, J.O. Liliemark, R.H. Farmen, C.R. Franks, M. Uytdenhoef, and C.O. Peterson Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia Ther Drug Monit 9 3 1987 263 271
176. D.B. Smith, J.M. Margison, S.B. Lucas, P.M. Wilkinson, and A. Howell Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin Cancer Chemother Pharmacol 19 2 1987 138 142
177. W.P. Petros, J.H. Rodman, J. Mirro, and W.E. Evans Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia Cancer Chemother Pharmacol 27 5 1991 397 400
178. J.L. Jurlina, A.R. Varcoe, and J.W. Paxton Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia Cancer Chemother Pharmacol 14 1 1985 21 25
179. H. Yoshida, M. Goto, and A. Honda Pharmacokinetics of doxorubicin and its active metabolite in patients with normal renal function and in patients on hemodialysis Cancer Chemother Pharmacol 33 6 1994 450 454
180. C.M. Camaggi, E. Strocchi, and P. Carisi Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study Cancer Chemother Pharmacol 30 4 1992 307 316
181. A. Sulkes, and J.M. Collins Reappraisal of some dosage adjustment guidelines Cancer Treat Rep 71 3 1987 229 233
182. L. Gianni, L. Vigano, and A. Locatelli Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer J Clin Oncol 15 5 1997 1906 1915
183. D.A. Rushing, S.R. Raber, K.A. Rodvold, S.C. Piscitelli, G.S. Plank, and D.A. Tewksbury The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer [see comments] Cancer 74 3 1994 834 841
184. D.J. Kerr, J. Graham, and J. Cummings The effect of verapamil on the pharmacokinetics of adriamycin Cancer Chemother Pharmacol 18 3 1986 239 242
185. G.C. Yee, W.R. Crom, F.H. Lee, R.D. Smyth, and W.E. Evans Bleomycin disposition in children with cancer Clin Pharmacol Ther 33 5 1983 668 673
186. S.T. Crooke, F. Luft, A. Broughton, J. Strong, K. Casson, and L. Einhorn Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function Cancer 39 4 1977 1430 1434
187. R.T. Dorr Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics Semin Oncol 19 2 Suppl 5 1992 3 8
188. W.E. Evans, J.A. Sinkule, W.R. Crom, L. Dow, A.T. Look, and G. Rivera Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer Cancer Chemother Pharmacol 7 2-3 1982 147 150
189. S.P. Lowis, A.D. Pearson, D.R. Newell, and M. Cole Etoposide pharmacokinetics in children: the development and prospective validation of a dosing equation Cancer Res 53 20 1993 4881 4889
190. V. Meresse, G. Vassal, and J. Michon Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Societe Francaise d'Oncologie Pediatrique J Clin Oncol 11 4 1993 630 637
191. S.P. Joel, R. Shah, and M.L. Slevin Etoposide dosage and pharmacodynamics Cancer Chemother Pharmacol 34 Suppl 1994 S69 S75
192. S.G. Arbuck, H.O. Douglass, and W.R. Crom Etoposide pharmacokinetics in patients with normal and abnormal organ function J Clin Oncol 4 11 1986 1690 1695
193. M. D'Incalci, C. Rossi, and M. Zucchetti Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function Cancer Res 46 5 1986 2566 2571
194. K.H. Pfluger, M. Hahn, and J.B. Holz Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions Cancer Chemother Pharmacol 31 5 1993 350 356
195. H.L. McLeod, and W.E. Evans Clinical pharmacokinetics and pharmacodynamics of epipodophyllotoxins Cancer Surv 17 1993 253 268
196. 4503A4 [published erratum appears in Mol Pharmacol 1995;48(3):568] Mol Pharmacol 45 2 1994 352 358
197. M.V. Relling, Y. Yanishevski, and J. Nemec Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia Leukemia 12 3 1998 346 352
198. J.H. Rodman, D.J. Murry, T. Madden, and V.M. Santana Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation J Clin Oncol 12 11 1994 2390 2397
199. G. Bisogno, F. Cowie, A. Boddy, H.D. Thomas, G. Dick, and C.R. Pinkerton High-dose cyclosporin with etoposide - toxicity and pharmacokinetic interaction in children with solid tumours Br J Cancer 77 12 1998 2304 2309
200. P.I. Clark, and M.L. Slevin The clinical pharmacology of etoposide and teniposide Clin Pharmacokinet 12 4 1987 223 252
201. G.M. Higa, M.A. Sarkar, and R.F. DeVore Pharmacodynamic profile of prolonged etoposide administration in patients with small cell lung cancer and non-Hodgkin's lymphoma Pharmacotherapy 19 1 1999 101 107
202. A.A. Miller, E.A. Tolley, H.B. Niell, C.F. Stewart, and J.P. Griffin Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer Cancer Chemother Pharmacol 31 2 1992 161 166
203. A.A. Miller, G.L. Rosner, M.J. Ratain, D.R. Hollis, M.R. Green, and R.L. Schilsky Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062) Clin Cancer Res 3 5 1997 719 725
204. P.I. Clark, M.L. Slevin, and S.P. Joel A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity J Clin Oncol 12 7 1994 1427 1435
205. H. Kunitoh, and K. Watanabe Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer J Clin Oncol 12 1 1994 83 89
206. S.P. Lowis, L. Price, A.D. Pearson, D.R. Newell, and M. Cole A study of the feasibility and accuracy of pharmacokinetically guided etoposide dosing in children Br J Cancer 77 12 1998 2318 2323
207. J.J. Holthuis, L.G. de Vries, and P.E. Postmus Pharmacokinetics of high-dose teniposide Cancer Treat Rep 71 6 1987 599 603
208. W.P. Petros, J.H. Rodman, and M.V. Relling Variability in teniposide plasma protein binding is correlated with serum albumin concentrations Pharmacotherapy 12 4 1992 273 277
209. D.K. Baker, M.V. Relling, C.H. Pui, M.L. Christensen, W.E. Evans, and J.H. Rodman Increased teniposide clearance with concomitant anticonvulsant therapy J Clin Oncol 10 2 1992 311 315
210. J.H. Rodman, W.L. Furman, M. Sunderland, G. Rivera, and W.E. Evans Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients J Clin Oncol 11 2 1993 287 293
211. W.E. Evans, J. Rodman, and M.V. Relling Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia Semin Hematol 28 3 Suppl 4 1991 15 21
212. E. Groninger, S.S. de Graaf, G.J. Meeuwsen-de Boer, W.J. Sluiter, and S. Poppema Vincristine-induced apoptosis in vivo in peripheral blood mononuclear cells of children with acute lymphoblastic leukaemia (ALL) Br J Haematol 111 3 2000 875 878
213. M.A. Jordan, R.H. Himes, and L. Wilson Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro Cancer Res 45 6 1985 2741 2747
214. L.I. Huschtscha, W.A. Bartier, C.E. Ross, and M.H. Tattersall Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro Br J Cancer 73 1 1996 54 60
215. Y. Takano, M. Okudaira, and B.V. Harmon Apoptosis induced by microtubule disrupting drugs in cultured human lymphoma cells. Inhibitory effects of phorbol ester and zinc sulphate Pathol Res Pract 189 2 1993 197 203
216. R.K. Srivastava, A.R. Srivastava, S.J. Korsmeyer, M. Nesterova, Y.S. Cho-Chung, and D.L. Longo Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase Mol Cell Biol 18 6 1998 3509 3517
217. J. Zhang, N. Alter, J.C. Reed, C. Borner, L.M. Obeid, and Y.A. Hannun Bcl-2 interrupts the ceramide-mediated pathway of cell death Proc Natl Acad Sci USA 93 11 1996 5325 5328
218. W.R. Crom, S.S. de Graaf, and T. Synold Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia J Pediatr 125 4 1994 642 649
219. C.E. Gidding, G.J. Meeuwsen de Boer, P. Koopmans, D.R. Uges, W.A. Kamps, and S.S. de Graaf Vincristine pharmacokinetics after repetitive dosing in children Cancer Chemother Pharmacol 44 3 1999 203 209
220. S.S.N. de Graaf, S.J. Kellie, and H. Bloemhof Proceedings of the Conference on Vincristine by Infusion: A Pharmacokinetic Study in Children with Brain Tumors 1995
221. Vendrig DE, Teeuwsen J, Holthuis JJ, et al. Pharmacokinetics of vinblastine and vincristine in patients. Thesis. University of Utrecht, The Netherlands, 1989.
222. E. Groninger, T. Meeuwsen-De Boar, and P. Koopmans Pharmacokinetics of vincristine monotherapy in childhood acute lymphoblastic leukemia Pediatr Res 52 1 2002 113 118
223. V.S. Sethi, D.V.J. Jackson, and D.R. White Pharmacokinetics of vincristine sulfate in adult cancer patients Cancer Res 41 9 Pt 1 1981 3551 3555
224. H.W. Van den Berg, Z.R. Desai, R. Wilson, G. Kennedy, J.M. Bridges, and R.G. Shanks The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination Cancer Chemother Pharmacol 8 2 1982 215 219
225. R.A. Bender, M.C. Castle, D.A. Margileth, and V.T. Oliverio The pharmacokinetics of [3H]-vincristine in man Clin Pharmacol Ther 22 4 1977 430 435
226. V.S. Sethi, and J.C. Kimball Pharmacokinetics of vincristine sulfate in children Cancer Chemother Pharmacol 6 2 1981 111 115
227. D.V.J. Jackson, M.C. Castle, and R.A. Bender Biliary excretion of vincristine Clin Pharmacol Ther 24 1 1978 101 107
228. Vendrig DE. Bioanalysis, stability, pharmacokinetics and electrochemistry of the vinca alkaloids (introduction). Thesis. University of Utrecht, The Netherlands, 1989.
229. J.A. Houghton, P.M. Torrance, and P.J. Houghton Chromatographic analysis of Vinca alkaloids in human neoplastic tissues and host (mouse) tissues after injection in vivo or after incubation in vitro Anal Biochem 134 2 1983 450 454
230. X.J. Zhou, M. Placidi, and R. Rahmani Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension Anticancer Res 14 3A 1994 1017 1022
231. X.R. Zhou Pan, E. Seree, and X.J. Zhou Involvement of human liver cytochrome P4503A in vinblastine metabolism: drug interactions Cancer Res 53 21 1993 5121 5126
232. X.J. Zhou, X.R. Zhou Pan, T. Gauthier, M. Placidi, P. Maurel, and R. Rahmani Human liver microsomal cytochrome P4503A isozymes mediated vindesine biotransformation. Metabolic drug interactions Biochem Pharmacol 45 4 1993 853 861
233. 450 CYP3A4-mediated metabolism: implications for the development of drug resistance J Pharmacol Exp Ther 294 1 2000 387 395
234. S.H. Ahn, M.W. Duffel, and J.P. Rosazza Oxidations of vincristine catalyzed by peroxidase and ceruloplasmin J Nat Prod 60 11 1997 1125 1129
235. J.D. Chan Pharmacokinetic drug interactions of vinca alkaloids: summary of case reports Pharmacotherapy 18 6 1998 1304 1307
236. K. Villikka, K.T. Kivisto, H. Maenpaa, H. Joensuu, and P.J. Neuvonen Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors Clin Pharmacol Ther 66 6 1999 589 593
237. Z.R. Desai, H.W. Van den Berg, J.M. Bridges, and R.G. Shanks Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 8 2 1982 211 214
238. M.J. Ratain, N.J. Vogelzang, and J.A. Sinkule Interpatient and intrapatient variability in vinblastine pharmacokinetics Clin Pharmacol Ther 41 1 1987 61 67
239. R. Rahmani, and X.J. Zhou Pharmacokinetics and metabolism of vinca alkaloids Cancer Surv 17 1993 269 281
240. M.J. Ratain, and N.J. Vogelzang Phase I and pharmacological study of vinblastine by prolonged continuous infusion Cancer Res 46 9 1986 4827 4830
241. C.A. Hurwitz, M.V. Relling, and S.D. Weitman Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study J Clin Oncol 11 12 1993 2324 2329
242. N.L. Seibel, and G.H. Reaman New microtubular agents in pediatric oncology Invest New Drugs 14 1 1996 49 54
243. M.H. Woo, M.V. Relling, and D.S. Sonnichsen Phase I targeted systemic exposure study of paclitaxel in children with refractory acute leukemias Clin Cancer Res 5 3 1999 543 549
244. U. Vaishampayan, R.E. Parchment, B.R. Jasti, and M. Hussain Taxanes: an overview of the pharmacokinetics and pharmacodynamics Urology 54 6A Suppl 1999 22 29
245. V.R. Panday, M.T. Huizing, and P.H. Willemse Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function Semin Oncol 24 4 Suppl 11 1997 S11 11
246. E.K. Rowinsky, M.R. Gilbert, and W.P. McGuire Sequences of taxol and cisplatin: a phase I and pharmacologic study J Clin Oncol 9 9 1991 1692 1703
247. M. Venturini, G. Lunardi, and L. Del Mastro Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity J Clin Oncol 18 10 2000 2116 2125
248. M.T. Huizing, A.C. Keung, and H. Rosing Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients J Clin Oncol 11 11 1993 2127 2135
249. E.K. Rowinsky, M. Jiroutek, P. Bonomi, D. Johnson, and S.D. Baker Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin Clin Cancer Res 5 4 1999 767 774